All In Biotech

BLA 761430 · Janssen Biotech

Imaavy

Nipocalimab-Aahu · Injection

NovelPriority reviewOrphan

CDER novel approval, Apr 29, 2025: To treat generalized myasthenia gravis

Last checked: Nov 20, 2026Latest source record: Aug 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Apr 29, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

21

10 Phase 3, 9 recruiting

FAERS reports

318

119 serious, 4 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 21, 2026.

IMAAVY is a neonatal Fc receptor blocker indicated for the treatment of: generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. ( 1.1 ) warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. ( 1.2 ) 1.1 Generalized Myasthenia Gravis (gMG) IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. 1.2 Warm Autoimmune Hemolytic Anemia (wAIHA) IMAAVY is indicated for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids.

Mechanism: Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 24, 2026 Supplement 2 · Efficacy · priority review OrphanLabelLetter
  • Apr 29, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
  • IMAAVY · NIPOCALIMAB-AAHU 1200MG/6.5ML(185MG/ML) · INJECTABLE, INJECTION · Prescription
  • IMAAVY · NIPOCALIMAB-AAHU 300MG/1.62ML(185MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Nipocalimab" as an intervention, any sponsor and status, largest first.

All 21 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective30
  • myasthenia gravis25
  • headache20
  • oedema peripheral20
  • fatigue18
  • dyspnoea16
  • influenza14
  • off label use14
  • product dose omission issue13
  • infusion related reaction11
  • rash11
  • therapeutic response decreased11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202588
2026230

Recalls

1 FDA enforcement reports for this application.

  • Sep 23, 2026 · Class II · Ongoing

    Presence of particulate matter.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.